Recursion Pharmaceuticals, an AI-driven biopharmaceutical company, announced layoffs affecting 20% of its staff as part of organizational streamlining and pipeline pruning. This step follows market volatility and reflects capital constraints impacting biopharma. Despite cutbacks, the company aims to maintain a cash runway into late 2027, fueled by milestone payments and operational efficiencies. Recursion's focus narrows to oncology and rare diseases as it integrates capabilities from its recent Exscientia acquisition to bolster its AI-driven drug discovery platform.